Interstitial lung disease (ILD) is an increasingly recognized complication of rheumatoid
arthritis (RA) contributing to significantly increased morbidity and mortality. Diagnosis can be …

Rationale: A previous trial of bosentan in idiopathic pulmonary fibrosis (IPF) showed a trend
to delayed IPF worsening or death. Also, improvements in some measures of dyspnea and …

OBJECTIVES: To analyze the clinical characteristics, outcomes, and patterns of association
with the different biologic agents used in all reported cases of adult patients developing …

Monoclonal antibodies have emerged as a new class of agents causing drug-related
pulmonary involvement in patients with systemic rheumatologic autoimmune diseases. The …

The outcome and cause of death of each lung disease directly associated with rheumatoid
arthritis (RA-LD) have been poorly investigated. A retrospective study was conducted of 144 …

Background Organizing pneumonia (OP) is a distinct clinical and pathologic entity. This
condition can be cryptogenic (COP) or secondary to other known causes (secondary OP). In …

We assessed the prevalence of interstitial lung disease (ILD) in a cohort of smokers included
in a lung cancer screening trial. Two observers independently reviewed, for the presence of …

Background Little is understood about the characteristics of dyspnea in patients with
interstitial lung disease (ILD), and its severity is likely influenced by multiple factors …

The composite physiologic index (CPI) was derived to represent the extent of fibrosis on
high-resolution computed tomography (HRCT), adjusting for emphysema in patients with …

Background In patients with heart failure from acquired cardiomyopathy, respiratory and
skeletal muscle weakness is common and is an independent predictor for adverse events …